Contact
searchSearch
HMP Global
Login

Colorectal Cancer Excellence Forum

Colorectal Cancer
Excellence Forum

Scott Kopetz, MD, PhD
Videos
Encorafenib Plus Cetuximab and mFOLFOX6 for Patients With BRAF V600E-Mutated Metastatic Colorectal Cancer
09/10/2025
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER study which demonstrated that encorafenib plus cetuximab and mFOLFOX6 improved survival outcomes compared to standard of care among previously untreated patients with BRAF...
Scott Kopetz, MD, PhD, discusses results from the BREAKWATER study which demonstrated that encorafenib plus cetuximab and mFOLFOX6 improved survival outcomes compared to standard of care among previously untreated patients with BRAF...
Scott Kopetz, MD, PhD, discusses...
09/10/2025
Oncology
John Strickler, MD
Videos
Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
08/21/2025
John Strickler, MD
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses...
08/21/2025
Oncology
Arvind Dasari, MD
Conference Coverage
Use of ctDNA Monitoring During Colorectal Cancer Treatment to Identify Patients Eligible for Curative-Intent Metastasis-Directed Therapy
08/05/2025
Arvind Dasari, MD
Arvind Dasari, MD, discusses study results which assessed the clinical utility of adding ctDNA monitoring to standard colorectal cancer treatment to better identify patients eligible for curative-intent metastasis-directed therapy.
Arvind Dasari, MD, discusses study results which assessed the clinical utility of adding ctDNA monitoring to standard colorectal cancer treatment to better identify patients eligible for curative-intent metastasis-directed therapy.
Arvind Dasari, MD, discusses...
08/05/2025
Oncology
Eric Christenson, MD
Videos
Nivolumab Plus Relatlimab For Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer
08/04/2025
Eric Christenson, MD
Eric Christenson, MD, discusses results from a phase 2 clinical trial highlighting the impact of combining nivolumab with relatlimab on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch...
Eric Christenson, MD, discusses results from a phase 2 clinical trial highlighting the impact of combining nivolumab with relatlimab on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch...
Eric Christenson, MD, discusses...
08/04/2025
Oncology
Dirk Arnold, MD, PhD
Conference Coverage
Amivantamab Rechallenge for Patients With Left-Sided Metastatic Colorectal Cancer
07/24/2025
Dirk Arnold, MD, PhD
Dirk Arnold, MD, PhD, discusses updated results from the OrigAMI-1 trial, which assessed amivantamab rechallenge in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer who experienced disease progression after treatment...
Dirk Arnold, MD, PhD, discusses updated results from the OrigAMI-1 trial, which assessed amivantamab rechallenge in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer who experienced disease progression after treatment...
Dirk Arnold, MD, PhD, discusses...
07/24/2025
Oncology
Filippo Pietrantonio, MD
Videos
Sotorasib Plus Panitumumab for Patients With KRAS G12C-Mutated Chemorefractory Metastatic Colorectal Cancer
07/17/2025
Filippo Pietrantonio
Filippo Pietrantonio, MD, discusses results from the CodeBreaK 300 study which assessed sotorasib plus panitumumab in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer.
Filippo Pietrantonio, MD, discusses results from the CodeBreaK 300 study which assessed sotorasib plus panitumumab in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer.
Filippo Pietrantonio, MD,...
07/17/2025
Oncology
Sheraz Yaqub, MD, PhD, Oslo University Hospital
Videos
Aspirin Did Not Improve Survival Outcomes for Patients With Metastatic Colorectal Cancer
06/13/2025
Sheraz Yaqub, MD, PhD
Sheraz Yaqub, MD, shares insights from a phase 3 trial evaluating aspirin as secondary prevention of colorectal cancer liver metastases.
Sheraz Yaqub, MD, shares insights from a phase 3 trial evaluating aspirin as secondary prevention of colorectal cancer liver metastases.
Sheraz Yaqub, MD, shares...
06/13/2025
Oncology
Marwan Fakih, MD, City of Hope Comprehensive Cancer Center
Videos
Sotorasib Plus Panitumumab May Improve Survival Outcomes for Chemorefractory Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
06/06/2025
Marwan Fakih, MD
Marwan Fakih, MD, discusses the phase 3 CodeBreaK 300 trial which evaluated sotorasib plus panitumumab for patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer.
Marwan Fakih, MD, discusses the phase 3 CodeBreaK 300 trial which evaluated sotorasib plus panitumumab for patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer.
Marwan Fakih, MD, discusses the...
06/06/2025
Oncology
Jue Wang, MD, UT Southwestern Medical Center
Videos
Managing Patients With Multiple Primary Cancers
05/08/2025
Jue Wang, MD
Jue Wang, MD, shares the case of a patient with 2 concurrent primary cancers: metastatic prostate cancer and metastatic colorectal cancer.
Jue Wang, MD, shares the case of a patient with 2 concurrent primary cancers: metastatic prostate cancer and metastatic colorectal cancer.
Jue Wang, MD, shares the case of...
05/08/2025
Oncology
Jue Wang, MD, UT Southwestern Medical Center
Videos
Managing Patients With Multiple Primary Cancers
05/08/2025
Jue Wang, MD
Jue Wang, MD, shares the case of a patient with 2 concurrent primary cancers: metastatic prostate cancer and metastatic colorectal cancer.
Jue Wang, MD, shares the case of a patient with 2 concurrent primary cancers: metastatic prostate cancer and metastatic colorectal cancer.
Jue Wang, MD, shares the case of...
05/08/2025
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use